RAGE Gene

Migration, Crosslink

📖

RAGE Gene

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-rage

📖 Wiki Page

gene1742 wordssynced 2026-04-02

RAGE Gene

Introduction

[Rage](/genes/rage) Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">
<div class="infobox-header">RAGE (AGER)</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> Advanced Glycation End-Product Receptor</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 6p21.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 177</div>
<div class="infobox-row"><strong>OMIM:</strong> 600403</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000204305</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q15120</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's Disease, Parkinson's Disease, Diabetes Complications, Atherosclerosis, Stroke</div>
</div>
</div>

Overview

[RAGE](/genes/rage) (Receptor for Advanced Glycation End-products), also known as AGER, encodes a pattern recognition receptor that binds diverse ligands including advanced glycation end products (AGEs), [amyloid-beta](/proteins/amyloid-beta) fibrils, HMGB1, and S100 proteins. RAGE is a key mediator of oxidative stress, neuroinflammation, and cell death in neurodegenerative diseases[@stern2002].

Function

Pattern Recognition Receptor

RAGE functions as a pattern recognition receptor with broad ligand specificity:

...

RAGE Gene

Introduction

[Rage](/genes/rage) Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene">
<div class="infobox-header">RAGE (AGER)</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> Advanced Glycation End-Product Receptor</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 6p21.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 177</div>
<div class="infobox-row"><strong>OMIM:</strong> 600403</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000204305</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q15120</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's Disease, Parkinson's Disease, Diabetes Complications, Atherosclerosis, Stroke</div>
</div>
</div>

Overview

[RAGE](/genes/rage) (Receptor for Advanced Glycation End-products), also known as AGER, encodes a pattern recognition receptor that binds diverse ligands including advanced glycation end products (AGEs), [amyloid-beta](/proteins/amyloid-beta) fibrils, HMGB1, and S100 proteins. RAGE is a key mediator of oxidative stress, neuroinflammation, and cell death in neurodegenerative diseases[@stern2002].

Function

Pattern Recognition Receptor

RAGE functions as a pattern recognition receptor with broad ligand specificity:

Advanced Glycation End-products (AGEs): Products of non-enzymatic glycation that accumulate with aging and diabetes
Amyloid-beta ([Aβ](/proteins/amyloid-beta)): RAGE binds Aβ fibrils and mediates Aβ-induced neurotoxicity
HMGB1: High mobility group box 1 protein released from damaged cells
S100 proteins: Calcium-binding proteins released during inflammation
Phosphatidylserine: Exposed on apoptotic cells[@bianchi2011]

Signaling Pathways

RAGE activation triggers multiple pro-inflammatory and pro-oxidant signaling cascades:

[NF-κB](/entities/nf-kb) pathway: Leads to increased expression of inflammatory cytokines
MAPK pathways: Including p38, JNK, and ERK
RAGE-dependent cell death: Activation of apoptotic pathways
Oxidative stress: Through NADPH oxidase activation
Inflammasome activation: IL-1β and IL-18 processing[@sims2010]

Disease Associations

Alzheimer's Disease

RAGE plays a multifaceted role in Alzheimer's disease:

Aβ-RAGE interaction: RAGE binds Aβ and mediates Aβ-induced neuronal dysfunction and microglial activation
Neuroinflammation: RAGE activation drives chronic neuroinflammation through NF-κB and cytokine release
Oxidative stress: RAGE increases [ROS](/entities/reactive-oxygen-species) production in neurons and glia
Blood-brain barrier: RAGE modulates BBB permeability and may facilitate Aβ entry into the brain
Therapeutic target: RAGE inhibitors are being investigated for AD treatment[@li2020]

Parkinson's Disease

In Parkinson's disease:

Dopaminergic neuron vulnerability: RAGE contributes to oxidative stress and inflammation in the substantia nigra
[α-Synuclein](/proteins/alpha-synuclein) interaction: RAGE may bind α-synuclein and promote its aggregation
Neuroinflammation: RAGE-mediated microglial activation contributes to dopaminergic neuron loss
Genetic variants: RAGE polymorphisms may influence PD risk[@choi2019]

Stroke and Ischemia

RAGE is involved in post-stroke pathophysiology:

Ischemic injury: RAGE expression increases following cerebral ischemia
Blood-brain barrier disruption: RAGE contributes to BBB breakdown after stroke
Reperfusion injury: RAGE mediates oxidative stress during reperfusion
Therapeutic potential: RAGE blockade may reduce post-stroke damage[@qiu2021]

Diabetes and Diabetic Complications

As RAGE was originally identified for its role in diabetes:

Diabetic neuropathy: RAGE contributes to neuronal dysfunction in diabetes
Vascular complications: RAGE promotes atherosclerosis and vascular damage
Peripheral neuropathy: RAGE-mediated inflammation affects peripheral nerves[@vincent2011]

Expression

RAGE exhibits cell-type-specific and condition-dependent expression:

High expression: Lung, heart, brain, spinal cord, kidney
Brain expression: [Neurons](/entities/neurons), [microglia](/entities/microglia), [astrocytes](/entities/astrocytes), brain endothelial cells, [pericytes](/cell-types/pericytes)
Induction by injury: RAGE expression increases dramatically following neuronal injury
Regional expression: High expression in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and spinal cord
Allen Brain Atlas: Expression data available at [Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=AGER)[@allen2020]

Structural Features

Receptor Architecture

RAGE is a multi-domain pattern recognition receptor:

Extracellular Domain: Contains a variable (V) domain and two constant (C1, C2) Ig-like domains for ligand binding

Transmembrane Helix: Single transmembrane domain anchors RAGE in the plasma membrane

Cytoplasmic Tail: Intracellular signaling domain interacts with multiple adaptor proteins

Ligand Binding Sites

The extracellular domain contains multiple ligand-binding pockets:

V domain: Primary binding site for AGEs and HMGB1
C1/C2 domains: Support interactions with Aβ fibrils and S100 proteins
Glycation sites: Non-enzymatic glycation enhances ligand affinity

Mermaid diagram (expand to render)

Downstream Signaling Cascades

NF-κB Pathway

RAGE activation triggers NF-κB nuclear translocation:

MyD88 recruitment: Adapter protein recruitment to RAGE cytoplasmic tail

IRAK activation: Interleukin-1 receptor-associated kinase activation

TRAF6 ubiquitination: downstream activation of IKK complex

IκB degradation: Release of sequestered NF-κB

Nuclear translocation: NF-κB enters nucleus[@hudson2008]

Oxidative Stress Generation

RAGE promotes ROS production through:

NADPH oxidase activation: Direct phosphorylation of p47phox
Mitochondrial dysfunction: Alters electron transport chain
Peroxidase activity: Induces hydrogen peroxide generation
Antioxidant depletion: Reduces cellular antioxidant capacity[xie2017]

Inflammasome Activation

RAGE directly activates the NLRP3 inflammasome:

ASC recruitment: Adapter protein recruitment to RAGE
Caspase-1 activation: Proteolytic processing of pro-caspase-1
Cytokine maturation: Processing of pro-IL-1β and pro-IL-18
Pyroptosis induction: Gasdermin D-mediated cell death

Therapeutic Implications

RAGE is a promising therapeutic target:

RAGE inhibitors: Small molecule inhibitors (e.g., FPS-ZM1) that block RAGE
Anti-RAGE antibodies: Monoclonal antibodies against RAGE
Soluble RAGE (sRAGE): Decoy receptor that sequesters RAGE ligands
Gene therapy: Approaches to reduce RAGE expression
Natural compounds: Some dietary flavonoids can inhibit RAGE signaling[@chen2022]

Clinical Biomarkers

sRAGE as Biomarker

Soluble RAGE (sRAGE) serves as a biomarker:

Diagnostic utility: Reduced sRAGE in CSF associated with neurodegeneration

Disease progression: sRAGE levels correlate with disease severity

Treatment response: Changes in sRAGE reflect therapeutic efficacy

Risk stratification: Low sRAGE predicts conversion from MCI to AD

RAGE Polymorphisms

Genetic variants affect disease risk:

-429T/C promoter SNP: Alters expression levels
G82S variant: Changes ligand binding affinity
G82S in diabetes: Associated with diabetic complications
Hypothetical variants: Require further validation

Biomarker Development

Current biomarker development efforts:

Serum sRAGE: ELISA-based detection
CSF sRAGE: More directly reflects CNS status
Soluble forms: Alternative splicing variants
Autoantibodies: Anti-RAGE antibodies as biomarkers

Drug Development

Small Molecule Inhibitors

Several RAGE inhibitors in development:

FPS-ZM1: High-affinity RAGE antagonist

PF-04447947: RAGE inhibitor in clinical trials

TTP-488: RAGE antagonist for diabetes

Natural compounds: Flavonoids and polyphenols

Antibody Approaches

Therapeutic antibodies target RAGE:

MAb 1756: Blocking antibody
Soluble RAGE decoys: Receptor mimics
Engineered variants: Enhanced ligand binding
Bispecific antibodies: Multiple targets

Gene Therapy

Gene therapy approaches include:

RAGE knockdown: shRNA-mediated silencing
CRISPR targeting: Precision editing
Promoter manipulation: Tissue-specific suppression
Viral delivery: AAV-based approaches

Pharmacological modulation

Clinical Status

RAGE-targeted therapies in clinical development:

Phase I trials: Safety and dosing studies
Phase II trials: Efficacy endpoints
Combination approaches: With standard of care
Biomarker enrichment: Patient selection strategies

Challenges

Key challenges in RAGE targeting:

Broad ligand specificity: Multiple ligands to block
Expression patterns: Normal vs pathological
Central vs peripheral: Blood-brain barrier penetration
Compensatory mechanisms: Upregulation with inhibition

Future Directions

Emerging research directions:

Structural studies: Cryo-EM of RAGE-ligand complexes
Single-cell analysis: Cell-type-specific effects
Spatial transcriptomics: Regional RAGE expression
Multi-omics integration: System-level understanding

Summary

Key Points

RAGE is a central mediator in neurodegenerative disease:

Pattern recognition: Multiple damage-associated molecular patterns

Pro-inflammatory: Drives chronic neuroinflammation

Pro-oxidative: Generates reactive oxygen species

Therapeutic target: Multiple drugs in development

Clinical Relevance

RAGE-targeted therapies show promise for:

Alzheimer's disease: Reducing neuroinflammation
Parkinson's disease: Protecting dopaminergic neurons
Stroke: Limiting post-ischemic damage
Diabetes: Managing complications

Research Gaps

Remaining questions include:

Receptor activation: Full structural mechanisms
Cell-type specificity: Which cells to target
Therapeutic window: Optimal dosing strategies
Biomarkers: Predictive patient selection

Research Models

Cellular Models

RAGE research utilizes cellular systems:

Primary neurons: Cultured cortical and hippocampal neurons
iPSC-derived cells: Induced pluripotent stem cell-derived neurons and glia
Microglia cell lines: BV2 and RAW264.7 cells
Organoid models: Brain organoids for three-dimensional studies

Animal Models

Transgenic mouse models include:

RAGE transgenic mice: Overexpress RAGE in brain
RAGE knockout mice: Complete gene deletion
Conditional knockins: Cell-type-specific expression
Double mutants: Cross with AD/PD model mice

Therapeutic Testing

Drug development pipelines use:

In vitro screening: Cell-based assays for RAGE inhibition
Explant cultures: Organotypic brain slice cultures
Behavioral testing: Learning and memory assessments
Biomarker endpoints: CSF and blood marker analysis

RAGE: A receptor for advanced glycation endproducts in the brain - Nature Reviews Neurology, 2021[@stern2002]

RAGE and Alzheimer's disease: Pathogenesis and therapeutic potential - Journal of Alzheimer's Disease, 2020[@li2020]

RAGE in Parkinson's disease: Beyond neuroinflammation - Movement Disorders, 2019[@choi2019]

RAGE and stroke: Molecular mechanisms and therapeutic targets - Neuropharmacology, 2021[@qiu2021]

Targeting RAGE for neuroprotection in neurodegenerative diseases - Pharmacology & Therapeutics, 2022[@chen2022]

External Links

[NCBI Gene: RAGE](https://www.ncbi.nlm.nih.gov/gene/177)
[UniProt: RAGE](https://www.uniprot.org/uniprot/Q15120)
[OMIM: RAGE](https://www.omim.org/entry/600403)
[Ensembl: RAGE](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204305)
[Allen Brain Atlas: AGER](https://human.brain-map.org/microarray/search/show?search_term=AGER)

Background

The study of Rage Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

Allen Human Brain Atlas

[Allen Human Brain Atlas - Gene Expression](https://human.brain-map.org/microarray/search/show?search_term=RAGE): Interactive gene expression data across the adult human brain

Allen Cell Type Atlas

[Allen Cell Type Atlas](https://celltypes.brain-map.org/): Single-cell transcriptomics data for neuronal and glial cell types

BrainSpan Transcriptome Atlas

[BrainSpan Atlas of the Developing Human Brain](https://www.brainspan.org/): Developmental gene expression data from prenatal to adult brain

Mouse Brain Atlas

[Allen Mouse Brain Atlas](https://mouse.brain-map.org/): Comprehensive gene expression maps in the mouse brain

Links verified: 2026-03-16

References

[Stern D, et al, RAGE: A receptor for advanced glycation endproducts in the brain (2002)](https://pubmed.ncbi.nlm.nih.gov/11836533/)

[Bianchi R, et al, RAGE in neural disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21850424/)

[Sims GP, et al, Inflammasome activation by RAGE (2010)](https://pubmed.ncbi.nlm.nih.gov/20192818/)

[Li XH, et al, RAGE and Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31884478/)

[Choi JG, et al, RAGE in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31305056/)

[Qiu J, et al, RAGE in stroke pathophysiology (2021)](https://pubmed.ncbi.nlm.nih.gov/33774129/)

[Vincent AM, et al, RAGE in diabetic complications (2011)](https://pubmed.ncbi.nlm.nih.gov/21353679/)

[Allen Brain Atlas, Human Brain Transcriptome (2020)](https://human.brain-map.org/)

[Chen Y, et al, Targeting RAGE for neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/34411758/)

[Hudson BI, et al, RAGE signaling in inflammation (2008)](https://pubmed.ncbi.nlm.nih.gov/18787072/)

[Ramasamy R, et al, RAGE and its ligands in Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23545654/)

[Fritz G, et al, RAGE in stroke pathophysiology (2013)](https://pubmed.ncbi.nlm.nih.gov/23533761/)

[Manfredini L, et al, RAGE in diabetic neuropathy (2020)](https://pubmed.ncbi.nlm.nih.gov/32342352/)

[Zhang L, et al, RAGE and neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29462967/)

[Li J, et al, RAGE in Parkinson's disease models (2018)](https://pubmed.ncbi.nlm.nih.gov/29731762/)

[Xie J, et al, RAGE and oxidative stress (2017)](https://pubmed.ncbi.nlm.nih.gov/28530418/)

Pathway Diagram

The following diagram shows the key molecular relationships involving RAGE Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

RAGE

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-rage
kg_node_id	RAGE
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a461a7a47f16
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-rage'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

134

Outgoing

182

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RAGE Gene

RAGE Gene

Introduction

Overview

Function

Pattern Recognition Receptor

RAGE Gene

Introduction

Overview

Function

Pattern Recognition Receptor

Signaling Pathways

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Stroke and Ischemia

Diabetes and Diabetic Complications

Expression

Structural Features

Receptor Architecture

Ligand Binding Sites

Downstream Signaling Cascades

NF-κB Pathway

Oxidative Stress Generation

Inflammasome Activation

Therapeutic Implications

Clinical Biomarkers

sRAGE as Biomarker

RAGE Polymorphisms

Biomarker Development

Drug Development

Small Molecule Inhibitors

Antibody Approaches

Gene Therapy

Pharmacological modulation

Clinical Status

Challenges

Future Directions

Summary

Key Points

Clinical Relevance

Research Gaps

Research Models

Cellular Models

Animal Models

Therapeutic Testing

See Also

External Links

Background

Brain Atlas Resources

Allen Human Brain Atlas

Allen Cell Type Atlas

BrainSpan Transcriptome Atlas

Mouse Brain Atlas

References

Pathway Diagram

💬 Discussion